preprint · Research Square (Research Square)
Abstract Background Coinfection of Mycobacterium tuberculosis (M.TB) and human immunodeficiency virus (HIV) accelerates immune deterioration. Approximately one in three people living with HIV dies due to TB. This is likely to hinder progress towards the achievement of the 2030 Sustainable Development Goal of ending the HIV and TB pandemic. Methods In this paper, we model HIV-TB interaction within the host using the deterministic approach. Further analysis of the progression of HIV in patients who were enrolled with TB and patients who developed TB during treatment is done using multi-state modelling. This study is done on HIV-TB co-infected young adults (15 to 34 years) from South Africa. HIV progression for this cohort is divided into 4 states (state 1: Undetectable viral load below 50 HIV RNA per mL; state 2: HIV RNA ranging from 50 to below 10 000 copies/mL; state 3: at least 10 000 HIV RNA copies/mL); and state 4: Death). Results Results from the analysis show that TB increases the odds of an unsuppressed viral load. This is quite notable for patients in state 2 where the log-linear effect of having TB at enrolment is approximately − 8.7 for the transition to state 1 and − 0.64 for the transition to state 3. At state 2 of HIV progression, the rate of virologic failure is also very high and most deaths are observed from this state. Conclusion This calls for the need to closely monitor HIV patients for any possibility of TB coinfection. This can be done by assigning treatment partners to all HIV patients.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.21203/rs.3.rs-3873834/v1
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.